ArticleJournal of neurological surgery. Part B, Skull base2026
Radiotherapy for Vestibular Schwannoma: Retrospective Cohort and Propensity Score Matching Analysis.
Article in Journal of neurological surgery. Part B, Skull base, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Surgery and stereotactic radiotherapy (SRT) are widely used for treating vestibular schwannomas (VS), but the impact of different SRT regimens remains debated. This study assesses outcomes of various SRT techniques in a large cohort. Materials and Methods: Retrospective cohort of consecutive patients treated in a large academic hospital between 2008 and 2024. All patients were treated with LINAC-based SRT. The study compared outcomes between single-dose SRS (12-15 Gy), five-fraction SRS (total of 25 Gy), and conventionally fractionated SRT (50.4 Gy in 28 fractions). The main outcome was progression-free survival (PFS). Results: The cohort included 197 patients, with a median age of 50.2 years, 65.5% of whom were female. The mean lesion size was 2.4 cm, and 61.4% of lesions were classified as high-class Koos (III and IV). Median follow-up was 54.0 months (6-142.1). Overall lesion control was 89.8% by RECIST 1.1 criteria, with no significant difference in PFS between the groups after propensity score matching. New hearing loss occurred in 14.7% of patients, whereas new facial palsy was reported in 3.0%. The presence of type-2 neurofibromatosis (NF2) was associated with poorer PFS (50.4 vs. 46.6 months, Conclusion: Different SRT regimens showed similar outcomes for lesion control and toxicity in VS patients, including those with NF2. This study supports LINAC-based SRT as a flexible treatment option, although further prospective studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.